

# **Catastrophic Antiphospholipid Syndrome Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034**

<https://marketpublishers.com/r/C058216B70EEEN.html>

Date: February 2025

Pages: 130

Price: US\$ 4,850.00 (Single User License)

ID: C058216B70EEEN

## **Abstracts**

The Global Catastrophic Antiphospholipid Syndrome Market was valued at USD 4.7 billion in 2024 and is expected to grow at a CAGR of 10.7% from 2025 to 2034. The market is driven by the rising prevalence of autoimmune disorders and growing awareness of CAPS, a life-threatening variant of antiphospholipid syndrome (APS). Technological advancements in diagnostics are enhancing early disease detection, increasing demand for effective treatments. Government and private sector research funding are further accelerating the development of novel therapies.

CAPS, also known as Asherson's syndrome, is a severe autoimmune disorder characterized by rapid thrombotic events affecting multiple organs. Due to the complexity of this condition, treatment approaches vary and typically include anticoagulation, corticosteroids, plasma exchange, and other immunosuppressive therapies. The market is segmented by treatment type, route of administration, and end-use settings.

Among treatments, immunosuppressive therapy remains the dominant segment, valued at USD 1.4 billion in 2022 and projected to reach USD 1.7 billion in 2024. These drugs, often combined with anticoagulants and corticosteroids, are vital for improving patient outcomes. Increasing clinical evidence supporting the efficacy of immunosuppressive therapy is bolstering market demand. Additionally, orphan drug designations by regulatory bodies such as the U.S. FDA and EMA are promoting the adoption of immunosuppressive treatments, including cyclophosphamide, rituximab, and corticosteroids.

The market is further categorized based on the route of administration, with parenteral

treatments leading, accounting for 65.7% of the market share in 2024. This segment is expected to grow at a CAGR of 10.6% through the forecast period. The severity of CAPS necessitates immediate medical intervention, making parenteral administration the preferred choice due to its rapid therapeutic effects. The rising use of biologic therapies such as rituximab and eculizumab via parenteral delivery is further strengthening market growth. Innovations in drug delivery systems, including infusion pumps and prefilled syringes, are enhancing treatment efficacy and expanding adoption.

In terms of end-use, hospitals represent the largest segment, projected to reach USD 7 billion by 2034, growing at a CAGR of 10.5%. Hospitals are equipped with advanced diagnostic and treatment facilities, making them the primary centers for CAPS management. Rising healthcare expenditures and improved hospital infrastructure are driving this segment's growth. Additionally, hospitals frequently collaborate with pharmaceutical companies and research organizations to facilitate clinical trials, bringing advanced therapies to patients. The increasing presence of specialized rheumatologists in hospital settings is further contributing to the expanding market.

The U.S. market alone generated USD 1.9 billion in 2024 and is expected to reach USD 5 billion by 2034. The growing number of autoimmune disease cases in the country is fueling demand for better treatment options. Increased investment in research and the adoption of modern diagnostic systems are accelerating market expansion. The rising use of anticoagulants such as warfarin and heparin among healthcare professionals is also supporting market growth.

## Contents

### CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market scope and definition
- 1.2 Research design
  - 1.2.1 Research approach
  - 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
  - 1.3.1 Base year calculation
  - 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
  - 1.5.1 Primary sources
  - 1.5.2 Data mining sources

### CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Industry 360° synopsis

### CHAPTER 3 INDUSTRY INSIGHTS

- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
  - 3.2.1 Growth drivers
    - 3.2.1.1 Increasing prevalence of autoimmune disorders
    - 3.2.1.2 Technological advancements in diagnostics and therapeutics
    - 3.2.1.3 Rising awareness of catastrophic antiphospholipid syndrome (CAPS)
    - 3.2.1.4 Increasing healthcare expenditure
  - 3.2.2 Industry pitfalls and challenges
    - 3.2.2.1 High treatment costs
    - 3.2.2.2 Limited availability of specialized treatment
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Future market trends
- 3.6 Porter's analysis
- 3.7 PESTEL analysis

### CHAPTER 4 COMPETITIVE LANDSCAPE, 2024

- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard

## **CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY TREATMENT, 2021 – 2034 (\$ MN)**

- 5.1 Key trends
- 5.2 Anticoagulants
- 5.3 Immunosuppressive therapy
- 5.4 Plasma exchange therapy
- 5.5 Intravenous immunoglobulin (IVIG)
- 5.6 Other treatments

## **CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY ROUTE OF ADMINISTRATION, 2021 – 2034 (\$ MN)**

- 6.1 Key trends
- 6.2 Oral
- 6.3 Parenteral

## **CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 – 2034 (\$ MN)**

- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Specialty clinics
- 7.4 Ambulatory surgical centers
- 7.5 Other end use

## **CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 (\$ MN)**

- 8.1 Key trends
- 8.2 North America

- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
  - 8.3.1 Germany
  - 8.3.2 UK
  - 8.3.3 France
  - 8.3.4 Spain
  - 8.3.5 Italy
  - 8.3.6 Netherlands
- 8.4 Asia Pacific
  - 8.4.1 China
  - 8.4.2 India
  - 8.4.3 Japan
  - 8.4.4 Australia
  - 8.4.5 South Korea
- 8.5 Latin America
  - 8.5.1 Brazil
  - 8.5.2 Mexico
  - 8.5.3 Argentina
- 8.6 Middle East and Africa
  - 8.6.1 South Africa
  - 8.6.2 Saudi Arabia
  - 8.6.3 UAE

## **CHAPTER 9 COMPANY PROFILES**

- 9.1 Abbott Laboratories
- 9.2 AbbVie
- 9.3 Boehringer Ingelheim International
- 9.4 Bristol Myers Squibb Company
- 9.5 Cadrenal Therapeutics
- 9.6 Eli Lilly and Company
- 9.7 F. Hoffmann-La Roche
- 9.8 Johnson & Johnson Services
- 9.9 Merck
- 9.10 Novartis
- 9.11 Pfizer
- 9.12 Sanofi

## I would like to order

Product name: Catastrophic Antiphospholipid Syndrome Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

Product link: <https://marketpublishers.com/r/C058216B70EEEN.html>

Price: US\$ 4,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C058216B70EEEN.html>